{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:26:25Z","timestamp":1760145985646,"version":"build-2065373602"},"reference-count":29,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Over the past years, the introduction of direct-acting antivirals (DAAs) revolutionized chronic hepatitis C treatment. We aimed to characterize and assess treatment efficacy in three specific groups of patients treated with DAAs: those with active solid malignant tumors (SMTs), hematological diseases (HDs) and hepatocellular carcinomas (HCCs). Methods: A total of 203 patients with active oncological disease (SMT n = 61, HD = 67, HCC n = 74) during DAA treatment in 2015\u20132020 selected from the EpiTer-2 database were analyzed retrospectively and compared to 12,983 patients without any active malignancy. Results: Extrahepatic symptoms were more frequent in HD patients (17.2% vs. SMT = 10.3%, HCC = 8.2%, without = 7.8%, p = 0.004). HCC patients characterized with the highest ALT activity (81 IU\/L vs. SMT = 59.5 IU\/L, HD = 52 IU\/L, without = 58 IU\/L, p = 0.001) more often had F4 fibrosis as well (86.11% vs. SMT = 23.3%, HD = 28.8%, controls = 24.4%, p = 0.001). A significant majority of subjects in HCC, HD and SMT populations completed the full treatment plan (HCC = 91%; n = 67, HD = 97%; n = 65, SMT = 100%; n = 62). Concerning the treatment efficacy, the overall sustained virologic response, excluding non-virologic failures, was reported in 93.6% HD, 90.16% SMT and 80.6% in HCC patients. Conclusions: As presented in our study, DAA therapy has proven to be highly effective and safe in patients with active SMTs and HDs. However, therapy discontinuations resulting from liver disease progression remain to be the major concern in HCC patients.<\/jats:p>","DOI":"10.3390\/cancers16173114","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T10:42:22Z","timestamp":1725878542000},"page":"3114","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Real-World Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C in Patients Active Malignancies"],"prefix":"10.3390","volume":"16","author":[{"given":"Maria","family":"D\u0105browska","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Medical University of Silesia, 40-635 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0139-4753","authenticated-orcid":false,"given":"Jerzy","family":"Jaroszewicz","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Medical University of Silesia, 40-635 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3078-8604","authenticated-orcid":false,"given":"Marek","family":"Sitko","sequence":"additional","affiliation":[{"name":"Department of Infectious and Tropical Diseases, Jagiellonian University, 30-688 Krak\u00f3w, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6072-4559","authenticated-orcid":false,"given":"Justyna","family":"Janocha-Litwin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Medical University Wroclaw, 51-149 Wroclaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0938-1084","authenticated-orcid":false,"given":"Dorota","family":"Zar\u0119bska-Michaluk","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Allergology, Jan Kochanowski University, 25-317 Kielce, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5406-4603","authenticated-orcid":false,"given":"Ewa","family":"Janczewska","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, Faculty of Health Sciences, Medical University of Silesia, 41-902 Bytom, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6319-9278","authenticated-orcid":false,"given":"Beata","family":"Lorenc","sequence":"additional","affiliation":[{"name":"Pomeranian Center of Infectious Diseases, Department of Infectious Diseases, Medical University of Gda\u0144sk, 80-214 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5640-5432","authenticated-orcid":false,"given":"Magdalena","family":"Tudrujek-Zdunek","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Medical University of Lublin, 20-081 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Parfieniuk-Kowerda","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Medical University of Bia\u0142ystok, 15-569 Bia\u0142ystok, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Klapaczy\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Hepatology, The National Institute of Medicine of the Ministry of Interior and Administration, 02-507 Warszawa, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Berak","sequence":"additional","affiliation":[{"name":"Daily Department of Hospital for Infectious Diseases in Warsaw, 01-201 Warszawa, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0141ukasz","family":"Socha","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hepatology and Liver Transplantation, Pomeranian Medical University, 71-455 Szczecin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Dobracka","sequence":"additional","affiliation":[{"name":"MedicalSpec Medical Center, 53-228 Wroc\u0142aw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1961-8519","authenticated-orcid":false,"given":"Dorota","family":"Dybowska","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University, 87-100 Toru\u0144, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W\u0142odzimierz","family":"Mazur","sequence":"additional","affiliation":[{"name":"Clinical Department of Infectious Diseases, Specialist Hospital in Chorz\u00f3w, Medical University of Silesia, 41-500 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1490-2219","authenticated-orcid":false,"given":"\u0141ukasz","family":"Wa\u017cny","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Medical University of Silesia, 40-635 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3394-1635","authenticated-orcid":false,"given":"Robert","family":"Flisiak","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Medical University of Bia\u0142ystok, 15-569 Bia\u0142ystok, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1515\/jtim-2017-0007","article-title":"Direct acting anti-hepatitis C virus drugs: Clinical pharmacology and future direction","volume":"5","author":"Geddawy","year":"2017","journal-title":"J. Transl. Intern. Med."},{"key":"ref_2","unstructured":"World Health Organization (2024, January 24). Global Health Sector Strategy on Viral Hepatitis 2016\u20132021. Towards Ending Viral Hepatitis. Available online: https:\/\/iris.who.int\/handle\/10665\/246177."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Tronina, O., Panczyk, M., Zar\u0119bska-Michaluk, D., Gotlib, J., and Ma\u0142kowski, P. (2023). Global Elimination of HCV\u2014Why Is Poland Still So Far from the Goal?. Viruses, 15.","DOI":"10.3390\/v15102067"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jvir.2019.12.809","article-title":"Direct-Acting Antivirals Improve Overall Survival in Interventional Oncology Patients with Hepatitis C and Hepatocellular Carcinoma","volume":"31","author":"Kamp","year":"2020","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Patauner, F., Stanzione, M., Stornaiuolo, G., Martone, V., Palladino, R., Coppola, N., Durante-Mangoni, E., and Zampino, R. (2022). Safety and Efficacy of Direct Antiviral Agents for Hepatitis C in Patients with Malignancies Other Than Liver Cancer: A Case Series. Pathogens, 11.","DOI":"10.3390\/pathogens11080860"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5603\/NJO.2023.0026","article-title":"Cancer incidence and mortality in Poland in 2020","volume":"73","author":"Wojciechowska","year":"2023","journal-title":"Nowotw. J. Oncol."},{"key":"ref_7","first-page":"213","article-title":"Boceprevir: A new hope against hepatitis C virus","volume":"3","author":"Brashier","year":"2012","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jsps.2022.07.005","article-title":"The effectiveness and safety of direct-acting antivirals for hepatitis C virus treatment: A single-center experience in Saudi Arabia","volume":"30","author":"Alarfaj","year":"2022","journal-title":"Saudi Pharm. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.4254\/wjh.v14.i3.525","article-title":"Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review","volume":"14","author":"Spera","year":"2022","journal-title":"World J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jhep.2019.04.017","article-title":"Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis","volume":"71","author":"Ji","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/jvh.12765","article-title":"A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study","volume":"25","author":"Barone","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1053\/j.gastro.2019.01.027","article-title":"Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study","volume":"156","author":"Singal","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/cld.1082","article-title":"Direct-Acting Antiviral Therapy and Hepatocellular Carcinoma","volume":"17","author":"Rich","year":"2021","journal-title":"Clin. Liver Dis."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Kanda, T., Matsumoto, N., Ishii, T., Arima, S., Shibuya, S., Honda, M., Sasaki-Tanaka, R., Masuzaki, R., Kanezawa, S., and Nishizawa, T. (2023). Chronic Hepatitis C: Acute Exacerbation and Alanine Aminotransferase Flare. Viruses, 15.","DOI":"10.3390\/v15010183"},{"key":"ref_17","first-page":"556","article-title":"Acute hepatitis C virus infection, 1986\u20132001: A rare cause of fulminant hepatitis in Chiba, Japan","volume":"51","author":"Kanda","year":"2004","journal-title":"Hepatogastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2362.1992.tb01507.x","article-title":"Role of hepatitis C virus infection in German patients with fulminant and subacute hepatic failure","volume":"22","author":"Theilmann","year":"1992","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s10620-022-07524-6","article-title":"Role of Hepatitis C Infection in Acute Liver Injury\/Acute Liver Failure in North America","volume":"68","author":"Rao","year":"2023","journal-title":"Dig. Dis. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hep.29344","article-title":"Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study","volume":"67","author":"Torres","year":"2018","journal-title":"Hepatology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/jmv.20263","article-title":"Clinical and virological characteristics of untreated patients with chronic hepatitis C who develop serum alanine aminotransferase flare-up","volume":"75","author":"Hiraga","year":"2005","journal-title":"J. Med. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/gut.2004.048009","article-title":"Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: A retrospective cohort study of 206 untreated patients","volume":"54","author":"Rumi","year":"2005","journal-title":"Gut"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/17425255.2019.1574744","article-title":"Hepatotoxicity induced by immune checkpoint inhibitors: A comprehensive review including current and alternative management strategies","volume":"15","author":"Jennings","year":"2019","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_24","first-page":"3","article-title":"Post-mortem neuropathologic examination of a 6-case series of CAR T-cell treated patients","volume":"27","author":"Caballero","year":"2022","journal-title":"Free Neuropathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1002\/hep.30988","article-title":"Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West","volume":"71","author":"Dang","year":"2020","journal-title":"Hepatology"},{"key":"ref_26","first-page":"1","article-title":"Evaluating short-term and long-term liver fibrosis improvement in hepatitis C patients post-DAA treatment","volume":"21","author":"Wang","year":"2024","journal-title":"J. Biomed. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1177\/1078155220969797","article-title":"Risks of hepatitis C virus reactivation in a real-life population of oncology patients treated in an academic center","volume":"27","author":"Boutin","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/jgh.14008","article-title":"Long-term liver stiffness assessment in hepatitis C virus patients undergoing antiviral therapy: Results from a 5-year cohort study","volume":"33","author":"Facciorusso","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_29","first-page":"767","article-title":"Evolution of patients with chronic hepatitis C infection with advanced fibrosis or cirrhosis cured with direct-acting antivirals. Long-term follow-up","volume":"45","year":"2022","journal-title":"Gastroenterol. Hepatol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/17\/3114\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:52:23Z","timestamp":1760111543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/17\/3114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":29,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["cancers16173114"],"URL":"https:\/\/doi.org\/10.3390\/cancers16173114","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2024,9,9]]}}}